Risk factors for cancer development in type 2 diabetes: A retrospective case-control study

BMC Cancer

Table 2 Adjusted risk of malignancy associated with antidiabetic medications, use vs. non-use

Antidiabetic medication	OR^a (95 % CI)	P value	OR^b (95 % CI)	P value	OR^c (95 % CI)	P value
Metformin	0.294 (0.182–0.478)	<0.001	0.318 (0.193–0.523)	<0.001	0.310 (0.183–0.525)	<0.001
Sulfonylurea	0.735 (0.493–1.094)	0.129	0.859 (0.547–1.349)	0.508	0.906 (0.563–1.456)	0.683
Acarbose	1.333 (0.640–2.776)	0.443	1.372 (0.635–2.967)	0.421	1.245 (0.564–2.747)	0.587
DPP-4 inhibitors	1.954 (0.698–5.468)	0.202	2.809 (0.947–8.331)	0.063	3.468 (1.082–11.112)	0.036
Insulin	1.964 (1.227–3.144)	0.005	1.509 (0.879–2.588)	0.135	1.735 (0.986–3.053)	0.056

^a adjusted for BMI, diabetes duration and metabolic control
^b adjusted for BMI, diabetes duration, metabolic control and antidiabetic medications use
^c adjusted for BMI, diabetes duration, metabolic control, antidiabetic medications use, smoking history, place of residence, presence of comorbidities and aspirin use
Data presented in bold are statistically significant

ISSN: 1471-2407